HIF1A and cancer: Targeting the SMURF2-HIF1α axis to modulate the degradation of critical proteins involved in therapeutic resistance could enhance cancer cells’ sensitivity to targeted therapies, offering a promising strategy to counteract these resistance mechanisms.